Results 1 to 10 of about 696,855 (303)

Assessment of Nonischemic Myocardial Fibrosis [PDF]

Journal of the American College of Cardiology, 2010
Myocardial fibrosis is recognized as the pathologic entity of extracellular matrix remodeling. Diffuse, reactive fibrosis is being increasingly recognized in a variety of conditions despite the absence of ischemia. Regardless of the etiology, fibrosis leads to increased myocardial stiffness thereby promoting cardiac dysfunction.
Christine Jellis, Jennifer Martin
exaly   +7 more sources

Drugs for treating myocardial fibrosis

Frontiers in Pharmacology, 2023
Myocardial fibrosis, which is a common pathological manifestation of many cardiovascular diseases, is characterized by excessive proliferation, collagen deposition and abnormal distribution of extracellular matrix fibroblasts.
Zhanhong Ren, Zixuan Zhang, Zixuan Zhang, Li Ling, Xiufen Liu, Xin Wang   +5 more
doaj   +3 more sources

RNA 5-Methylcytosine Modification in Myocardial Fibrosis [PDF]

Reviews in Cardiovascular Medicine
Myocardial fibrosis represents a common pathological hallmark of various cardiovascular diseases progressing to heart failure, with the immunoinflammatory response playing a pivotal role in the pathogenesis of myocardial fibrosis.
Bohan Li, Yan Hao, Wendan Tian, Wei Liu
doaj   +2 more sources

Immunomodulation of Myocardial Fibrosis

JACC: Basic to Translational Science, 2023
Immunotherapy is a potential cornerstone in the treatment of myocardial fibrosis. During a myocardial insult or heart failure, danger signals stimulate innate immune cells to produce chemokines and profibrotic cytokines, which initiate self-escalating inflammatory processes by attracting and stimulating adaptive immune cells. Stimulation of fibroblasts
Sikking, Maurits A., Stroeks, Sophie L.VM., Marelli-Berg, Federica, Heymans, Stephane R.B., Ludewig, Burkhard, Verdonschot, Job A.J.   +5 more
openaire   +4 more sources

Blood Immune Cell Alterations in Patients with Hypertensive Left Ventricular Hypertrophy and Heart Failure with Preserved Ejection Fraction

Journal of Cardiovascular Development and Disease, 2023
(1) Background: Chronic inflammation and fibrosis are key players in cardiac remodeling associated with left ventricular hypertrophy (LVH) and heart failure with a preserved ejection fraction (HFpEF). Monocytes and T-helpers (Th) are involved in both pro-
Artem Ovchinnikov, Anastasiya Filatova, Alexandra Potekhina, Tatiana Arefieva, Anna Gvozdeva, Fail Ageev, Evgeny Belyavskiy   +6 more
doaj   +1 more source

Myocardial fibrosis [PDF]

Tidsskrift for Den norske legeforening, 2018
Myokardfibrose oppstår sekundært til kardial belastning eller skade. I denne oversiktsartikkelen presenteres sentrale aspekter ved myokardfibrose.Vi foretok 2 søk i PubMed som til sammen ga 417 treff. Artiklenes relevans ble vurdert på grunnlag av tittel, sammendrag og eventuell fulltekst. 44 sentrale artikler ble inkludert.Myokardfibrose klassifiseres
Torvald, Espeland, Ida Gjervold, Lunde, Brage, H Amundsen, Lars, Gullestad, Svend, Aakhus   +4 more
openaire   +2 more sources

Hypertensive myocardial fibrosis [PDF]

Nephrology Dialysis Transplantation, 2005
A variety of cardiac structural and functional changes, such as increased left ventricular mass (LVM), left atrial and aortic root enlargement, LV dysfunction, impairment of coronary reserve and prolonged ven- tricular repolarization, have been described in patients with long-standing arterial hypertension [1,2].
CUSPIDI, CESARE, Ciulla, M, Zanchetti, A.   +2 more
openaire   +5 more sources

Myocardial Fibrosis in Athletes [PDF]

Mayo Clinic Proceedings, 2016
Myocardial fibrosis (MF) is a common phenomenon in the late stages of diverse cardiac diseases and is a predictive factor for sudden cardiac death. Myocardial fibrosis detected by magnetic resonance imaging has also been reported in athletes. Regular exercise improves cardiovascular health, but there may be a limit of benefit in the exercise dose ...
van de Schoor, Freek R., Aengevaeren, Vincent L., Hopman, Maria T.E., Oxborough, David L., George, Keith P., Thompson, Paul D., Eijsvogels, Thijs M.H.   +6 more
openaire   +3 more sources

MicroRNA-325-3p Targets Human Epididymis Protein 4 to Relieve Right Ventricular Fibrosis in Rats with Pulmonary Arterial Hypertension

Cardiovascular Therapeutics, 2022
Background. Pulmonary arterial hypertension (PAH) usually causes right ventricular dysfunction, which is closely related to cardiac fibrosis. But cardiac fibrosis mechanism remains unclear.
Yi Tang, Xiaowei Huo, Junyu Liu, Yijin Tang, Min Zhang, Wenlin Xie, Zhaofen Zheng, Jin He, Jiayan Lian   +8 more
doaj   +1 more source

SARC Gene Mutation Is Associated With Myocardial Fibrosis Measured by Histopathology and Cardiac Magnetic Resonance in Patients With Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Sarcomere gene mutation and myocardial fibrosis are both associated with poorer clinical outcomes in patients with hypertrophic cardiomyopathy (HCM).
Manyun Huang, Jian Zhang, Changpeng Song, Shuiyun Wang, Zhou Zhou, Hongyue Wang, Shihua Zhao, Kunlun Yin, Li Li, Shujuan Yang, Xinxin Zheng, Jie Lu, Xiaohong Huang   +12 more
doaj   +1 more source